Monthly Archives: November 2011
By Guest Blogger | Published: November 30, 2011
Fernando Muzzio and Mauricio Futran propose a plan to turn around pharmaceutical manufacturing in the US. Pharmaceutical manufacturing in the US is in rapid decline. Higher regulatory standards for efficacy and safety, among other reasons, have led to a significant level of difficulty in replacing “blockbusters” developed in the 1980s and 1990s that are now coming [...]
By Julian Upton | Published: November 30, 2011
GSK’s Andrew Witty underlined his growing concerns with the business climate in Europe with his comments to the UK’s High Pay Commission last week. The Commission, set up by left-wing pressure group Compass, reported on the ‘corrosive’ effects of ‘boardroom excess’ and called for greater transparency in the setting of executive pay. The pay of [...]
By Ben Comer | Published: November 22, 2011
Tiered pricing, or selling critical medicines to developing countries at a standardized discount price, can improve access in the short term, but arbitrary demographic groupings and misaligned incentives often stack the deck in favor of manufacturers, not patients.
By Guest Blogger | Published: November 22, 2011
The bigger the company, the thicker the sclerosis, the more they need to suck out the fat, writes Bill Drummy. Consider this: In 2011, IMS projects US Rx market growth to be 2.7 percent. The top 10 pharma companies account for 50 percent of the entire market’s revenue, but will deliver only 10 percent of the [...]
By Julian Upton | Published: November 22, 2011
The fact that the eurozone is in a tailspin is hardly ‘news’, but when heads start rolling as fast as they have done recently in Greece, Italy, and now Spain, it leaves the unsettling feeling that the heat on an already intense situation has been turned up one more notch.